{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-014601","form_type":"8-K","ticker":"XFOR","cik":"0001501697","company_name":"X4 Pharmaceuticals, Inc","filed_at":"2025-03-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.812090+00:00","generated_at":"2026-05-24T05:41:05.395197+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"X4 Pharma FY2024 net rev $2.6M; Phase 3 CN trial on track; restructuring cuts spend $30-35M","bullets":["XOLREMDI net product revenue $2.6M from May 2024 launch through YE; cost of revenue $0.8M.","Net loss FY2024 $37.5M (incl. $105M PRV gain); cash $102.8M; pro-forma runway into 1H 2026.","Phase 3 4WARD trial for chronic neutropenia activated at ~90% sites; full enrollment expected Q3/Q4 2025; top-line data 2H 2026.","Protocol amendment: enroll only moderate/severe CN (ANC<1000); co-primary endpoint refined to uniform ANC increase ≥500 cells/µL.","Strategic restructuring reduces annual spend by $30-35M; includes headcount reduction, closing Vienna facility, and right-sizing US team."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-014601","json":"https://secwatch.observer/filing/0001628280-25-014601.json","markdown":"https://secwatch.observer/filing/0001628280-25-014601.md","text":"https://secwatch.observer/filing/0001628280-25-014601.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1501697/000162828025014601/0001628280-25-014601-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1501697/000162828025014601/xfor-20250325.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T05:41:05.395197+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}